Cargando…
A Phase II study of S-1 plus oral leucovorin in heavily treated metastatic colorectal cancer patients
PURPOSE: Fewer treatment options are available for refractory metastatic colorectal cancer (mCRC). In early trials, S-1 monotherapy was effective for mCRC patients after chemotherapy failure and its combination with oral leucovorin therapy offers promising results in untreated mCRC. Hence, we conduc...
Autores principales: | Hsu, Hung-Chih, Chou, Wen-Chi, Kuan, Feng-Che, Lee, Kuan-Der, Rau, Kun-Ming, Huang, Jen-Seng, Yang, Tsai-Sheng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252780/ https://www.ncbi.nlm.nih.gov/pubmed/30538555 http://dx.doi.org/10.2147/CMAR.S179345 |
Ejemplares similares
-
Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer
por: Koizumi, W., et al.
Publicado: (2010) -
A single-arm phase II trial of combined chemotherapy with S-1, oral leucovorin, and bevacizumab in heavily pre-treated patients with metastatic colorectal cancer
por: Yamaguchi, Kazuhisa, et al.
Publicado: (2015) -
UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer
por: Petrioli, R, et al.
Publicado: (2004) -
UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer
por: Alliot, C
Publicado: (2004) -
Alternating irinotecan with oxaliplatin combined with UFT plus leucovorin (SCOUT) in metastatic colorectal cancer
por: Sheikh, H Y, et al.
Publicado: (2008)